OneOncology's Larry Bilbrey outlines network-level contracting, data security, physician review of AI output, and clear ...

Recognizing Typical Lesions, Locations, and Chronicity" takes up the question of how clinicians can recognize HS reliably. Dr ...

Two new approvals reshape the complicated UTI landscape within a single year: an intravenous option revived after ...

CEO Susan Cantrell previews AMCP Nexus 2026, discussing AI, drug pricing, emerging therapies, and a decade of change in ...

UW Medicine’s Bessie A. Young, MD, MPH, explains how high-risk APOL1 variants, ancestry, and environmental factors shape kidney disease risk.

Providence’s Katherine R. Tuttle, MD, FASN, explains why semaglutide is preferred in T2D and CKD and how guidelines sequence ...

Senu Apewokin, MD, explains why C diff in ICU and chemotherapy patients may reflect colonization, not hospital transmission.

Given the role of immunization in reducing the incidence and prevalence—as well as morbidity and mortality—of vaccine-preventable diseases, 4 wider adoption of vaccination administration is ...

Jennifer Flythe, MD, MPH, discusses individualizing dialysis volume management and why guideline-directed therapy use lags in advanced CKD.

Relapse outcomes were largely null in major RCTs, including SOLAR and VIDAMS, despite numerically lower ARR in some analyses ...

Clinicians are voicing growing frustration over electronic medical record (EMR) inboxes, insurance peer-to-peer calls, and ...

Columbia’s Jai Radhakrishnan, MD, MS, explains how FSGS differs by phenotype and why new IgA nephropathy drugs reach so few ...